Efficacy of rapid IV administration of valproic acid for status epilepticus.

Abstract

Although not approved by the US Food and Drug Administration for the treatment of status epilepticus (SE), valproic acid (VPA) is an emerging option for this purpose. The authors reviewed 63 patients (30 men) with SE treated with IV VPA (average dose, 31.5 mg/kg). Analysis of demographic, clinical, and treatment information indicated an overall efficacy of 63.3% and favorable tolerance of rapid administration.

• Authors: N A Limdi, A V Shimpi, E Faught, C R Gomez, J G Burneo
• Journal: Neurology (Neurology) Vol. 64 Issue 2 Pg. 353-5 (Jan 25 2005) ISSN: 1526-632X [Electronic] United States
• PMID: 15668440 (Publication Type: Journal Article, Review)

Chemical References

• Anticonvulsants
• Valproic Acid

Topics

• Anticonvulsants (administration & dosage, therapeutic use)
• Comorbidity
• Drug Administration Schedule
• Drug Evaluation
• Female
• Humans
• Infusions, Intravenous
• Male
• Middle Aged
• Retrospective Studies
• Status Epilepticus (drug therapy)
• Treatment Outcome
• Valproic Acid (administration & dosage, therapeutic use)